With the deal, announced Nov. 24, Novartis gains Medicine Co.’s cholesterol-lowering drug Inclisiran, which uses a new technique called RNA interference to help especially hard-to-treat patients.
If FDA-approved, Inclisiran is predicted to reach peak annual sales of $4 billion, according to Bloomberg.
“We’re hoping to reimagine treatment of the leading global cause of death,” Novartis CEO Vas Narasimhan tweeted Nov. 24. ” This could be a strong step forward in Novartis’ transformation into a focused medicines company.”
Shares of Medicines Co. were up by 23 percent in trading before U.S. exchanges opened Nov. 25.
Read the full article here.
More articles on pharmacy:
AHA, CVS Health backed secretive anti-pharma group
EpiPen, Humira among drugs Warren wants to regulate
31 drugmakers at high risk for bankruptcy in 2020
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
